Basel, January 12, 2014 - Novartis announced today, that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect having decided to pursue a career opportunity outside of the organization.
Holzkirchen, Germany, December 19, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie's HUMIRA®) - the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease.
Munich, December 18, 2013 - Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).
Basel, December 9, 2013 - Novartis today announced that patients with myelofibrosis initially randomized to treatment with Jakavi® (ruxolitinib) lived longer than those randomized to treatment with placebo or conventional therapy, as described in several analyses from the Phase III COMFORT-I and COMFORT-II studies.
Basel, December 9, 2013 -Princeton University has announced that a vaccination program with Novartis meningococcal serogroup B (MenB) vaccine, Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), began today following a campus outbreak that has affected at least eight students.
Basel, December 9, 2013 - Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna® (nilotinib) compared to Glivec® (imatinib)* at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines),,,.
Basel, December 7, 2013 - Novartis is highlighting new research from members of the faculty at the University of Pennsylvania's Perelman School of Medicine (Penn) on the investigational chimeric antigen receptor (CAR) therapy, CTL019.
Basel, December 6, 2013 - Novartis today announced that results of a Phase III trial of the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib plus dexamethasone alone.
Basel, December 5, 2013 - Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company's innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company's Malaria Initiative.